

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 31, 2023

ATARA BIOTHERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware <small>(State or Other Jurisdiction of Incorporation or Organization)</small>	001-36548 <small>(Commission File No.)</small>	46-0920988 <small>(IRS Employer Identification No.)</small>
2380 Conejo Spectrum Street, Suite 200 Thousand Oaks, CA <small>(Address of Principal Executive Offices)</small>	91320 <small>(Zip Code)</small>	
Registrant's Telephone Number, Including Area Code: (805) 623-4211		
Not Applicable <small>(Former Name or Former Address, if Changed Since Last Report)</small>		

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, par value \$0.0001 per share	ATRA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On February 3, 2023, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), announced that Utpal Koppikar, the Company’s Executive Vice President, Chief Financial Officer, notified the Company of his intention to resign from the Company effective as of March 31, 2023.

On March 31, 2023, Mr. Koppikar resigned from the Company and entered into a consulting agreement with the Company, pursuant to which Mr. Koppikar will provide consulting services to the Company for a six-month term. Mr. Koppikar will be paid a consulting fee of \$2,800 monthly for up to a specified number of consulting hours per month and will receive additional compensation of \$175 per hour in excess of such specified number of consulting hours. Mr. Koppikar’s outstanding equity awards will continue to vest during the consulting term.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Atara Biotherapeutics, Inc.

By:

/s/ Amar Murugan

Amar Murugan

Executive Vice President, Chief Legal Officer

Dated: March 31, 2023
